Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials

• Published in: Prostaglandins, leukotrienes and essential fatty acids leukotrienes and essential fatty acids, 2021-05, Vol.168, p.102282-102282, Article 102282
• Main Authors: Bahbah, Eshak I., Shehata, Mohamed S.A., Alnahrawi, Safwat Ibrahim, Sayed, Ahmed, Menshawey, Amr, Fisal, Ahmed, Morsi, Mahmoud, Gabr, Mohamed Essam, Elbasit, Mohamed Salah Abd
• Format: Article
• Language: English
• Subjects: Anticholesteremic Agents - therapeutic use; Benzodiazepines - therapeutic use; Cardiovascular disease; Cardiovascular Diseases - drug therapy; Cardiovascular Diseases - metabolism; Cardiovascular Diseases - pathology; Cholesterol; Evacetrapib; Hypercholesterolemia; Hypercholesterolemia - drug therapy; Hypercholesterolemia - metabolism; Hypercholesterolemia - pathology; Randomized Controlled Trials as Topic; Risk Factors
• ISSN: 0952-3278; 1532-2823
• DOI: 10.1016/j.plefa.2021.102282

•Evacetrapib could significantly increases the HDL and Apo-A1 levels.•Evacetrapib could significantly decreases the LDL cholesterol and Apo-B levels.•Evacetrapib associated with lower risk of total AEs.•Evacetrapib was not associated with prolonged QT interval.•Evacetrapib was able to gain trust after the off-target side effects of torcetrapib. Low-density lipoprotein cholesterol (LDL-C) is causally related to cardiovascular disease. Inhibition of cholesteryl ester transfer protein with Evacetrapib may provide an additional treatment option for patients who do not reach their LDL-C goal with statins or patients who cannot tolerate statins. We aimed to evaluate the safety and efficacy of Evacetrapib in patients with inadequately-controlled hypercholesterolemia and high cardiovascular risk. A computer literature search for PubMed, Scopus, and Science Direct was carried out from inception to 2019 and was updated from January 2019 till March 2021. We included only RCTs. Data were pooled as a mean difference in a random-effect model using the Mantel-Haenzel (M-H) method. We used Open Meta [Analyst] software (by the center of evidence-based medicine, Oxford University, UK). Five studies (n = 12,937 patients) reported in five articles were included in this meta-analysis. The overall pooled estimate showed that LDL-C was significantly lower in the evacetrapib group than the placebo group (MD -34.07 mg/dL, 95% CI [-40.66, -27.49], p